These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11374797)

  • 1. Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease.
    Surowiak P; Dziegiel P; Zabel M; Matkowski R; Kornafel J
    Folia Histochem Cytobiol; 2001; 39(2):143-4. PubMed ID: 11374797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of estrogen receptor (ER) and estrogen-dependent pS2 protein expression in cells of mammary ductal carcinoma.
    Surowiak P; Dziegiel P; Zabel M; Matkowski R; Kornafel J
    Folia Histochem Cytobiol; 2001; 39(2):141-2. PubMed ID: 11374796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer.
    Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Delivelioti K; Gogas J; Kyrkou K
    Acta Cytol; 1997; 41(3):713-6. PubMed ID: 9167689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of pS2-protein in breast cancer].
    Kawabata K; Watanabe K; Ozaki S
    Rinsho Byori; 1996 Jul; 44(7):647-52. PubMed ID: 8741495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status.
    Looi LM; Azura WW; Cheah PL; Ng MH
    Pathology; 2001 Aug; 33(3):283-6. PubMed ID: 11523925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
    Gillesby BE; Zacharewski TR
    Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
    Jansen RL; Hupperets PS; Arends JW; Joosten-Achjanie SR; Volovics A; Hillen HF; Schouten HC
    Anticancer Res; 1998; 18(1B):577-82. PubMed ID: 9568180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of pS2 estrogen-inducible protein in primary breast cancer.
    Horiguchi J; Iino Y; Takei H
    Oncology; 1996; 53(1):12-5. PubMed ID: 8570124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7-year course of the disease.
    Surowiak P; Dziegiel P; Matkowski R; Kornafel J; Wojnar A; Zabe M
    Folia Histochem Cytobiol; 2002; 40(2):199-200. PubMed ID: 12056644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance.
    Corte MD; Tamargo F; Alvarez A; Rodríguez JC; Vázquez J; Sánchez R; Lamelas ML; González LO; Allende MT; García-Muñiz JL; Fueyo A; Vizoso F
    Breast Cancer Res Treat; 2006 Mar; 96(1):63-72. PubMed ID: 16267614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
    Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
    Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers.
    Surowiak P; Materna V; Györffy B; Matkowski R; Wojnar A; Maciejczyk A; Paluchowski P; Dziegiel P; Pudełko M; Kornafel J; Dietel M; Kristiansen G; Zabel M; Lage H
    Br J Cancer; 2006 Aug; 95(3):339-46. PubMed ID: 16892043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression.
    Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Nesković-Konstantinović Z; Branković-Magić M
    Neoplasma; 2001; 48(1):1-6. PubMed ID: 11327531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of estrogen receptor in formalin-fixed and paraffin-embedded breast carcinoma: correlation with histological patterns.
    Schmitt FC; Andrade LM; de Lucca LA
    Rev Paul Med; 1992; 110(4):158-62. PubMed ID: 1341005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
    Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
    Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule.
    Santeusanio G; Mauriello A; Ventura L; Liberati F; Colantoni A; Lasorella R; Spagnoli LG
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):275-84. PubMed ID: 11127919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.